R&D News | pharmaphorum

News

Metagenomi prices IPO and NeOnc joins list of hopefuls

Gene editing start-up Metagenomi and cancer specialist NeOnc Technologies have announced the terms of their initial public offerings, in another sign that investor interes

News

4DMT gene therapy cuts need for Eylea in wet AMD trial

A mid-stage trial of 4D Molecular Therapeutics gene therapy for eye disease age-related macular degeneration (AMD) 4D-150 has shown promising signs of efficacy, plus a red

News

First patient treated with Moderna's PD-1/IDO1 cancer shot

The first patient has been treated in a phase 1/2 clinical trial of an experimental Moderna vaccine designed to generate antibodies against PD-L1 and IDO1 – two targets th

News

Vera prices $250m offer, and other biotech financings

Our round-up of recent biotech financings is headed by a $250 million public offering for late clinical-stage biotech Vera Therapeutics, with an initial public offering (I

News

Takeda grabs late-stage haematology drug from Protagonist

Takeda has bolstered its near-term pipeline in rare haematological disorders by licensing rights to a polycythaemia vera (PV) treatment being developed by Protagonist Therapeutics.

News

Intellia’s president and chief executive John Leonard

Intellia’s CRISPR drug could offer one-shot HAE treatment

A single dose of a gene-editing drug being developed by Intellia Therapeutics almost eliminated attacks in patients with hereditary angioedema (HAE) in a clinical trial, p

Metagenomi prices IPO and NeOnc joins list of hopefuls

4DMT gene therapy cuts need for Eylea in wet AMD trial

First patient treated with Moderna's PD-1/IDO1 cancer shot

Vera prices $250m offer, and other biotech financings

Takeda grabs late-stage haematology drug from Protagonist

Intellia’s CRISPR drug could offer one-shot HAE treatment

FDA declines to approve AbbVie's Botox follow-up

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks